BioCentury

8:00 AM GMT, Dec 5, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

GLPG0634: Phase II data

Furthermore, once- and twice-daily GLPG0634 led to ACR50 response rates of 25% and 58.3%, respectively, vs. 8.3% for placebo (p=0.0591 for pooled data vs. placebo), while ACR70 response rates were 16.7% and 25%, respectively, vs. 0%

Read the full 361 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.